JBIO at a glance
Jade Biosciences, Inc. (JBIO, SEC CIK 1798749) filed its latest 10-K annual report on March 6, 2026, a 10-Q quarterly report on November 13, 2026, an 8-K current report on November 13, 2026 and Form 4 insider filings as recently as June 26, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding Jade Biosciences, Inc. (JBIO) shares worth $282.4 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 26 funds
- $282.4M · −1 vs prior quarter
- Latest 8-K
- Nov 13, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $0, unchanged YoY, with no product sales
- Net loss $35.1M vs $25.2M YoY, operating margin not applicable due to no revenue
- JADE101 R&D $12.1M vs $6.0M, strongest program; JADE201 $3.5M vs $6.7M, weakest
- Cash and investments $475.7M, operating cash use $96.6M for nine months
- June offering net proceeds $161.6M, management expects funding for at least twelve months
AI summary of the JBIO 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Press release announces Jade Biosciences’ financial results for the quarter ended September 30, 2026
- Results details are contained in Exhibit 99.1, the furnished earnings release
Item EX-99.1: Item EX-99.1
- Q3 net loss $35.1M, up from $25.2M, reflecting accelerating investment in clinical development
- Cash, cash equivalents and investments $475.7M, supporting operations and capital needs into Q4 2028
Item 8.01: Other Events
- JADE301 showed selective IFN-ß neutralization, with 11.3 pM binding affinity and 13 pM pSTAT inhibition
- Dermal fibroblast MX-1 inhibition reached 11 pM, approximately 8-fold more potent than dazukibart
Item 2.02: Results of Operations and Financial Condition
- Press release announces Jade Biosciences’ financial results for quarter ended June 30, 2026
- Exhibit 99.1 contains the detailed results, providing the primary investor reference for the period
Item EX-99.1: Item EX-99.1
- Positive interim JADE101 data: approximately 70% mean IgA reduction after one 700 mg dose, supporting potential every-12-week maintenance dosing
- JADE101 Phase 2 underway with interim data expected in 2027; Phase 3 planned for first half of 2027 pending FDA feedback
AI summaries of JBIO 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for JBIO
Don't miss the next JBIO filing
- Alerts as it files. A push when JBIO files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut JBIO, by share count.
- Ask anything. An AI agent that reads every JBIO filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Eisner Mark | A | Jun 25, 2026 | 47,675 | - |
| Fairmount Funds Management LLC | A | Jun 9, 2026 | 34,843 | - |
| Lavelle Erin | A | Jun 9, 2026 | 34,843 | - |
| Klein Lawrence Otto | A | Jun 9, 2026 | 34,843 | - |
| CAIN CHRISTOPHER W. | A | Jun 9, 2026 | 34,843 | - |
| DOBMEIER ERIC | A | Jun 9, 2026 | 34,843 | - |
| Dahms Bradford D. | A | Feb 12, 2026 | 226,875 | - |
| King Andrew James | A | Feb 12, 2026 | 41,250 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$81.4M | -$74.6M | -$113.5M |
| Net Income | -$75.5M | -$69.6M | -$127.4M |
| Balance Sheet | |||
| Total Assets | $127.4M | $80.3M | $349.8M |
| Equity | $109.5M | $76.4M | $332.5M |
| ROE | -69.0% | -91.1% | -38.3% |
| Per Share | |||
| EPS | $-2.87 | $-2.44 | $-3.19 |
| Cash Flow | |||
| Operating CF | -$56.8M | -$71.2M | -$94.7M |
| CapEx | $142K | - | $196K |
Source: XBRL data in Jade Biosciences, Inc. (JBIO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate JBIO share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 26 | $282.4M |
| Q2 2026 | 27 | $558.5M |
| Q1 2026 | 21 | $185.1M |
| Q4 2025 | 20 | $212.1M |
| Q3 2025 | 16 | $85.8M |
| Q2 2025 | 13 | $91.0M |
- T. Rowe Price Group+1.37M (+5165%)
- Franklin Resources+1.02M (+36%)
- BlackRock+565.3K (+20%)
- State Street Corp+267.7K (+11%)
- Blackstone Group+241.3K (+55%)
- Bank of America Corp−297.0K (-61%)
- Renaissance Technologies LLC−52.5K (-71%)
- Ameriprise Financial−25.9K (-24%)
- Citigroup−21.1K (-39%)
- Wells Fargo & Co−17.5K (-59%)
- FMR LLC (Fidelity)−9.13M
- AQR Capital Management−13.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 123 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
JBIO filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 13, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 13, 2026 | - | Analysis | - |
| 8-K | Sep 30, 2026 | - | Analysis | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| SC 13G | Jul 17, 2026 | - | - | |
| 8-K | Jul 1, 2026 | - | Analysis | - |
| 4 | Jun 26, 2026 | - | - | - |
| 8-K | Jun 26, 2026 | - | Analysis | - |
| 4 | Jun 11, 2026 | - | - | - |
| 8-K | Jun 11, 2026 | - | Analysis | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 8-K | Jun 4, 2026 | - | Analysis | |
| 8-K | Jun 1, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 8-K | Apr 22, 2026 | - | Analysis | - |
| 8-K | Apr 2, 2026 | - | Analysis | - |
| 10-K | Mar 6, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 6, 2026 | - | Analysis | - |
| SC 13G | Feb 17, 2026 | - | - | |
| SC 13G | Feb 17, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
JBIO SEC filings: frequently asked questions
Which institutions hold JBIO stock?
As of September 30, 2026, the largest Jade Biosciences, Inc. (JBIO) holders among the 13F filers tracked by SignalX were Franklin Resources ($57.3 million), BlackRock ($47.3 million), State Street Corp ($36.6 million), Vanguard Capital Management LLC ($33.0 million), JPMorgan Chase & Co ($20.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did JBIO report in its latest 8-K?
Jade Biosciences, Inc. (JBIO) filed an 8-K on November 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release announces Jade Biosciences’ financial results for the quarter ended September 30, 2026.
What are the latest JBIO SEC filings?
Jade Biosciences, Inc. (JBIO) filed its latest 10-K annual report on March 6, 2026, a 10-Q quarterly report on November 13, 2026, an 8-K current report on November 13, 2026 and a Form 4 insider filing on June 26, 2026.
What is JBIO's SEC CIK number?
Jade Biosciences, Inc. (JBIO)'s SEC Central Index Key (CIK) is 1798749. EDGAR lists every JBIO filing under that number.
Ask anything about JBIO
The research agent reads JBIO's filings, financials, insider trades and 13F holders, then answers with sources.